SecBot SecBot
SECBOTREPLAY Home › Report › XENE

XENE · NDA submitted; MDD data Dec 2026

Xenon Pharmaceuticals Inc. · 8-K filed Nov 9, 2026 at 16:00 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 9, 2026 at 16:00 ET

Xenon reported Q3 2026 results with a net loss of $110.4M, wider than the $90.9M loss in Q3 2025, driven by higher R&D spending. The key catalyst is the NDA submission for azetukalner in focal seizures and the upcoming X-NOVA2 MDD topline data readout in December 2026, though a voluntary pause on new enrollment in MDD/BPD studies introduces uncertainty.

  • NDA for azetukalner in focal seizures submitted to FDA in September 2026
  • Phase 3 X-NOVA2 MDD study enrollment completed; topline data expected December 2026
  • Voluntary pause on new patient enrollment in ongoing Phase 3 MDD and BPD studies announced in September 2026
  • Positive Phase 1 data for XEN1701 (NaV1.7) and XEN1120 (KV7) pain programs; Phase 2 POC studies expected H1 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access